We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AstraZeneca has scored another win with Imfinzi (durvalumab), showing that the checkpoint inhibitor in combination with standard chemotherapy improved both overall and progression-free survival for patients with advanced biliary tract cancer (BTC), a rare, aggressive disease with extremely low 5-year survival rates. Read More
Sanofi’s and Regeneron Pharmaceuticals’ blockbuster monoclonal antibody Dupixent (dupilumab) gained ground on two fronts last week: an approval for asthma in young children and positive phase 3 trial data for a notoriously difficult-to-treat skin condition with no approved therapy. Read More
The genetically modified pigs, which the FDA approved in December 2020 for biomedical and food use, are less likely to trigger an immune reaction in humans. Read More
For the cohort of participants needing high-flow oxygen, interferon beta-1a alone was also associated with more serious side effects, specifically, worsening respiratory responses, NIH said. Read More
Vertex Pharmaceuticals said a patient with a 40-year history of Type 1 diabetes experienced a 91 percent reduction in daily insulin dose after an infusion of its VX-880 stem-cell-derived islet cell replacement therapy. Read More
Tofersen, Biogen’s potential blockbuster for amyotrophic lateral sclerosis (ALS) caused by mutations of the SOD1 gene, has missed its primary endpoint of improved function in a highly anticipated trial. Read More
AZD1222, which is not authorized in the U.S., is currently approved for use in the UK and EU, while Valneva is not yet approved for use anywhere. Read More
Liver cancer patients who received AstraZeneca’s blockbuster human monoclonal antibody Imfinzi (durvalumab) paired with the company’s anti-CTLA4 antibody tremelimumab in a phase 3 trial lived longer. Read More